{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T01:52:28Z","timestamp":1781488348099,"version":"3.54.1"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Institutes of Health\/National Cancer Institute","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]},{"DOI":"10.13039\/100022884","name":"Tempus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019714","name":"Foundation Medicine","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019714","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01404-2","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T19:17:56Z","timestamp":1775848676000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 study"],"prefix":"10.1038","volume":"10","author":[{"given":"Jacopo","family":"Venturini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet A.","family":"Baysal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy A.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi Rodon","family":"Ahnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ecaterina Elena","family":"Dumbrava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kahle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Vining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolia Maria","family":"Tsimberidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"1404_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31\u201346 (2022).","journal-title":"Cancer Discov."},{"key":"1404_CR2","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","volume":"6","author":"R Huang","year":"2021","unstructured":"Huang, R. & Zhou, P. K. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct. Target Ther. 6, 254 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"1404_CR3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41392-023-01548-8","volume":"8","author":"Q Li","year":"2023","unstructured":"Li, Q. et al. A new wave of innovations within the DNA damage response. Signal Transduct. Target Ther. 8, 338 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"1404_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124\u2013128 (2015).","journal-title":"Science"},{"key":"1404_CR5","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.trecan.2023.07.002","volume":"9","author":"D Bhamidipati","year":"2023","unstructured":"Bhamidipati, D. & Subbiah, V. Tumor-agnostic drug development in dMMR\/MSI-H solid tumors. Trends Cancer 9, 828\u2013839 (2023).","journal-title":"Trends Cancer"},{"key":"1404_CR6","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord, C. J. & Ashworth, A. PARP inhibitors: Synthetic lethality in the clinic. Science 355, 1152\u20131158 (2017).","journal-title":"Science"},{"key":"1404_CR7","unstructured":"Administration, U. S. F. a. D. List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools), https:\/\/www.fda.gov\/medical-devices\/in-vitro-diagnostics\/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools (2025)."},{"key":"1404_CR8","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/bjc.2011.382","volume":"105","author":"M Javle","year":"2011","unstructured":"Javle, M. & Curtin, N. J. The role of PARP in DNA repair and its therapeutic exploitation. Br. J. Cancer 105, 1114\u20131122 (2011).","journal-title":"Br. J. Cancer"},{"key":"1404_CR9","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40265-015-0345-6","volume":"75","author":"ED Deeks","year":"2015","unstructured":"Deeks, E. D. Olaparib: first global approval. Drugs 75, 231\u2013240 (2015).","journal-title":"Drugs"},{"key":"1404_CR10","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","volume":"384","author":"ANJ Tutt","year":"2021","unstructured":"Tutt, A. N. J. et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N. Engl. J. Med. 384, 2394\u20132405 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1404_CR11","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/annonc\/mdz012","volume":"30","author":"ME Robson","year":"2019","unstructured":"Robson, M. E. et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann. Oncol. 30, 558\u2013566 (2019).","journal-title":"Ann. Oncol."},{"key":"1404_CR12","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1200\/JCO.22.01549","volume":"41","author":"P DiSilvestro","year":"2023","unstructured":"DiSilvestro, P. et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1\/GOG 3004 trial. J. Clin. Oncol. 41, 609\u2013617 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1404_CR13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda, A. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 620\u2013631 (2021).","journal-title":"Lancet Oncol."},{"key":"1404_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan, T. et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N. Engl. J. Med. 381, 317\u2013327 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1404_CR15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson, M. et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523\u2013533 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1404_CR16","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono, J. et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382, 2091\u20132102 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1404_CR17","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad, F. et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1094\u20131108 (2023).","journal-title":"Lancet Oncol."},{"key":"1404_CR18","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","volume":"31","author":"JK Litton","year":"2020","unstructured":"Litton, J. K. et al. Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann. Oncol. 31, 1526\u20131535 (2020).","journal-title":"Ann. Oncol."},{"key":"1404_CR19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal, N. et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 402, 291\u2013303 (2023).","journal-title":"Lancet"},{"key":"1404_CR20","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","volume":"35","author":"BJ Monk","year":"2024","unstructured":"Monk, B. J. et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann. Oncol. 35, 981\u2013992 (2024).","journal-title":"Ann. Oncol."},{"key":"1404_CR21","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1200\/JCO.18.02238","volume":"37","author":"JM Del Campo","year":"2019","unstructured":"Del Campo, J. M. et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial. J. Clin. Oncol. 37, 2968\u20132973 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1404_CR22","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","volume":"41","author":"KN Chi","year":"2023","unstructured":"Chi, K. N. et al. Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer. J. Clin. Oncol. 41, 3339\u20133351 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1404_CR23","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/S1470-2045(20)30061-9","volume":"21","author":"JA Ledermann","year":"2020","unstructured":"Ledermann, J. A. et al. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 21, 710\u2013722 (2020).","journal-title":"Lancet Oncol."},{"key":"1404_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","volume":"84","author":"W Abida","year":"2023","unstructured":"Abida, W. et al. Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study. Eur. Urol. 84, 321\u2013330 (2023).","journal-title":"Eur. Urol."},{"key":"1404_CR25","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Tutt","year":"2018","unstructured":"Tutt, A. et al. Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat. Med. 24, 628\u2013637 (2018).","journal-title":"Nat. Med."},{"key":"1404_CR26","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41416-019-0582-7","volume":"122","author":"MM Wattenberg","year":"2020","unstructured":"Wattenberg, M. M. et al. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br. J. Cancer 122, 333\u2013339 (2020).","journal-title":"Br. J. Cancer"},{"key":"1404_CR27","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","volume":"28","author":"PC Fong","year":"2010","unstructured":"Fong, P. C. et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28, 2512\u20132519 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1404_CR28","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nrc3007","volume":"11","author":"AC Begg","year":"2011","unstructured":"Begg, A. C., Stewart, F. A. & Vens, C. Strategies to improve radiotherapy with targeted drugs. Nat. Rev. Cancer 11, 239\u2013253 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"1404_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev-med-081313-121208","volume":"66","author":"M Goldstein","year":"2015","unstructured":"Goldstein, M. & Kastan, M. B. The DNA damage response: implications for tumor responses to radiation and chemotherapy. Annu. Rev. Med. 66, 129\u2013143 (2015).","journal-title":"Annu. Rev. Med."},{"key":"1404_CR30","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/annonc\/mdw697","volume":"28","author":"UA Matulonis","year":"2017","unstructured":"Matulonis, U. A. & Monk, B. J. PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist? Ann. Oncol. 28, 443\u2013447 (2017).","journal-title":"Ann. Oncol."},{"key":"1404_CR31","doi-asserted-by":"publisher","unstructured":"Martorana, F., Da Silva, L. A., Sessa, C. & Colombo, I. Everything comes with a price: the toxicity profile of DNA-damage response targeting agents. Cancers 14, https:\/\/doi.org\/10.3390\/cancers14040953 (2022).","DOI":"10.3390\/cancers14040953"},{"key":"1404_CR32","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.tranon.2019.10.010","volume":"13","author":"B Pellegrino","year":"2020","unstructured":"Pellegrino, B. et al. Homologous recombination repair deficiency and the immune response in breast cancer: a literature review. Transl. Oncol. 13, 410\u2013422 (2020).","journal-title":"Transl. Oncol."},{"key":"1404_CR33","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1084\/jem.20180139","volume":"215","author":"T Li","year":"2018","unstructured":"Li, T. & Chen, Z. J. The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J. Exp. Med. 215, 1287\u20131299 (2018).","journal-title":"J. Exp. Med."},{"key":"1404_CR34","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41586-022-04847-2","volume":"607","author":"C Hong","year":"2022","unstructured":"Hong, C. et al. cGAS-STING drives the IL-6-dependent survival of chromosomally instable cancers. Nature 607, 366\u2013373 (2022).","journal-title":"Nature"},{"key":"1404_CR35","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13045-019-0835-1","volume":"12","author":"AM Tsimberidou","year":"2019","unstructured":"Tsimberidou, A. M. et al. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J. Hematol. Oncol. 12, 145 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"1404_CR36","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega, F. et al. Oncogenic signaling pathways in the cancer genome atlas. Cell 173, 321\u2013337.e310 (2018).","journal-title":"Cell"},{"key":"1404_CR37","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2018.03.014","volume":"33","author":"AC Berger","year":"2018","unstructured":"Berger, A. C. et al. A comprehensive pan-cancer molecular study of gynecologic and breast cancers. Cancer Cell 33, 690\u2013705.e699 (2018).","journal-title":"Cancer Cell"},{"key":"1404_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00442-4","volume":"7","author":"D Wang","year":"2023","unstructured":"Wang, D. et al. Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays. NPJ Precis. Oncol. 7, 103 (2023).","journal-title":"NPJ Precis. Oncol."},{"key":"1404_CR39","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.trecan.2021.04.009","volume":"7","author":"G El Tekle","year":"2021","unstructured":"El Tekle, G. et al. Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us. Trends Cancer 7, 823\u2013836 (2021).","journal-title":"Trends Cancer"},{"key":"1404_CR40","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/s41588-020-0703-5","volume":"52","author":"M Mina","year":"2020","unstructured":"Mina, M., Iyer, A., Tavernari, D., Raynaud, F. & Ciriello, G. Discovering functional evolutionary dependencies in human cancers. Nat. Genet. 52, 1198\u20131207 (2020).","journal-title":"Nat. Genet."},{"key":"1404_CR41","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/ng.3168","volume":"47","author":"MD Leiserson","year":"2015","unstructured":"Leiserson, M. D. et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat. Genet. 47, 106\u2013114 (2015).","journal-title":"Nat. Genet."},{"key":"1404_CR42","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ccell.2017.06.010","volume":"32","author":"M Mina","year":"2017","unstructured":"Mina, M. et al. Conditional selection of genomic alterations dictates cancer evolution and oncogenic dependencies. Cancer Cell 32, 155\u2013168.e156 (2017).","journal-title":"Cancer Cell"},{"key":"1404_CR43","doi-asserted-by":"publisher","first-page":"6486","DOI":"10.1158\/0008-5472.CAN-18-1814","volume":"78","author":"Z Wang","year":"2018","unstructured":"Wang, Z. et al. Comutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade. Cancer Res. 78, 6486\u20136496 (2018).","journal-title":"Cancer Res."},{"key":"1404_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2024.103786","volume":"145","author":"FD Duzanic","year":"2025","unstructured":"Duzanic, F. D. & Penengo, L. The interferon response at the intersection of genome integrity and innate immunity. DNA Repair 145, 103786 (2025).","journal-title":"DNA Repair"},{"key":"1404_CR45","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13046-022-02469-0","volume":"41","author":"C Shi","year":"2022","unstructured":"Shi, C. et al. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy. J. Exp. Clin. Cancer Res. 41, 268 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1404_CR46","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41568-021-00386-6","volume":"21","author":"RM Chabanon","year":"2021","unstructured":"Chabanon, R. M. et al. Targeting the DNA damage response in immuno-oncology: developments and opportunities. Nat. Rev. Cancer 21, 701\u2013717 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"1404_CR47","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","volume":"9","author":"T Sen","year":"2019","unstructured":"Sen, T. et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 9, 646\u2013661 (2019).","journal-title":"Cancer Discov."},{"key":"1404_CR48","doi-asserted-by":"publisher","unstructured":"Parkes, E. E. et al. Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer. J. Natl. Cancer Inst. 109, https:\/\/doi.org\/10.1093\/jnci\/djw199 (2017).","DOI":"10.1093\/jnci\/djw199"},{"key":"1404_CR49","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou, C. et al. PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 9, 722\u2013737 (2019).","journal-title":"Cancer Discov."},{"key":"1404_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li, H. et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol. Cancer 19, 107 (2020).","journal-title":"Mol. Cancer"},{"key":"1404_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05564-z","volume":"9","author":"O Kondrashova","year":"2018","unstructured":"Kondrashova, O. et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat. Commun. 9, 3970 (2018).","journal-title":"Nat. Commun."},{"key":"1404_CR52","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(25)00683-X","volume":"406","author":"K Fizazi","year":"2025","unstructured":"Fizazi, K. et al. Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. Lancet 406, 461\u2013474 (2025).","journal-title":"Lancet"},{"key":"1404_CR53","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1200\/JCO.23.00339","volume":"42","author":"J Mateo","year":"2024","unstructured":"Mateo, J. et al. Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound trial. J. Clin. Oncol. 42, 571\u2013583 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1404_CR54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s12672-025-03775-7","volume":"17","author":"B Ye","year":"2026","unstructured":"Ye, B. et al. The value of DNA repair gene and TP53 co-mutation in predicting the response of non-small cell lung cancer to immunotherapy. Discov. Oncol. 17, 7 (2026).","journal-title":"Discov. Oncol."},{"key":"1404_CR55","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1200\/JCO.2017.75.7740","volume":"36","author":"MY Teo","year":"2018","unstructured":"Teo, M. Y. et al. Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1\/PD-L1 blockade in advanced urothelial cancers. J. Clin. Oncol. 36, 1685\u20131694 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1404_CR56","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.20892\/j.issn.2095-3941.2020.0708","volume":"19","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer. Cancer Biol. Med. 19, 1139\u20131149 (2021).","journal-title":"Cancer Biol. Med."},{"key":"1404_CR57","doi-asserted-by":"publisher","first-page":"4135","DOI":"10.1158\/1078-0432.CCR-19-3529","volume":"26","author":"B Ricciuti","year":"2020","unstructured":"Ricciuti, B. et al. Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer. Clin. Cancer Res. 26, 4135\u20134142 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1404_CR58","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/jpm12010008","volume":"12","author":"O Fahmy","year":"2021","unstructured":"Fahmy, O. et al. Oncological response and predictive biomarkers for the checkpoint inhibitors in castration-resistant metastatic prostate cancer: a systematic review and meta-analysis. J. Pers. Med 12, 8 (2021).","journal-title":"J. Pers. Med"},{"key":"1404_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.009","author":"AC Hardy-Bessard","year":"2025","unstructured":"Hardy-Bessard, A. C. et al. Dostarlimab and niraparib in primary advanced ovarian cancer. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.009 (2025).","journal-title":"Ann. Oncol."},{"key":"1404_CR60","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","volume":"21","author":"SM Domchek","year":"2020","unstructured":"Domchek, S. M. et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study. Lancet Oncol. 21, 1155\u20131164 (2020).","journal-title":"Lancet Oncol."},{"key":"1404_CR61","doi-asserted-by":"publisher","first-page":"3839","DOI":"10.1200\/JCO.23.00233","volume":"41","author":"ES Antonarakis","year":"2023","unstructured":"Antonarakis, E. S. et al. Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial. J. Clin. Oncol. 41, 3839\u20133850 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1404_CR62","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1200\/JCO.2024.42.16_suppl.506","volume":"42","author":"EF Cobain","year":"2024","unstructured":"Cobain, E. F. et al. Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer. J. Clin. Oncol. 42, 506\u2013506 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1404_CR63","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-7334701\/v1","author":"W Park","year":"2025","unstructured":"Park, W. et al. Pembrolizumab and Olaparib (POLAR) maintenance therapy in metastatic pancreatic cancer with or without homologous repair deficiency: a biomarker selected phase II trial. Res. Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-7334701\/v1 (2025).","journal-title":"Res. Sq."},{"key":"1404_CR64","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41591-024-02808-y","volume":"30","author":"B Besse","year":"2024","unstructured":"Besse, B. et al. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial. Nat. Med. 30, 716\u2013729 (2024).","journal-title":"Nat. Med."},{"key":"1404_CR65","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41416-024-02776-7","volume":"131","author":"R Kristeleit","year":"2024","unstructured":"Kristeleit, R. et al. PARP inhibition with rucaparib alone followed by combination with atezolizumab: phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers. Br. J. Cancer 131, 820\u2013831 (2024).","journal-title":"Br. J. Cancer"},{"key":"1404_CR66","doi-asserted-by":"publisher","first-page":"5542","DOI":"10.1200\/JCO.2025.43.16_suppl.5542","volume":"43","author":"RL Roux","year":"2025","unstructured":"Roux, R. L. et al. Ceralasertib (cerala) + olaparib (ola) in patients (pts) with homologous recombination repair (HRR)-deficient platinum-sensitive relapsed ovarian cancer (OC) after progression on prior PARP inhibitor (PARPi) treatment (tx). J. Clin. Oncol. 43, 5542\u20135542 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1404_CR67","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","volume":"29","author":"SL Wethington","year":"2023","unstructured":"Wethington, S. L. et al. Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian cancer. Clin. Cancer Res. 29, 2800\u20132807 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1404_CR68","doi-asserted-by":"publisher","unstructured":"Valdez, B. C. et al. Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in breast and ovarian cancer cells: implications for novel therapeutic combinations. Int. J. Mol. Sci. 25 https:\/\/doi.org\/10.3390\/ijms25179241 (2024).","DOI":"10.3390\/ijms25179241"},{"key":"1404_CR69","doi-asserted-by":"publisher","first-page":"361","DOI":"10.18632\/oncotarget.28588","volume":"15","author":"BC Valdez","year":"2024","unstructured":"Valdez, B. C. et al. Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy. Oncotarget 15, 361\u2013373 (2024).","journal-title":"Oncotarget"},{"key":"1404_CR70","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596\u2013614.e514 (2021).","journal-title":"Cell"},{"key":"1404_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1\u201310 (2013).","journal-title":"Immunity"},{"key":"1404_CR72","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1158\/1078-0432.CCR-24-3628","volume":"31","author":"Z Nian","year":"2025","unstructured":"Nian, Z., Dou, Y. & Wei, H. p53: an immune ecosystem manipulator. Clin. Cancer Res 31, 5120\u20135127 (2025).","journal-title":"Clin. Cancer Res"},{"key":"1404_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00159-2","volume":"5","author":"AM Tsimberidou","year":"2021","unstructured":"Tsimberidou, A. M. et al. Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. NPJ Precis. Oncol. 5, 21 (2021).","journal-title":"NPJ Precis. Oncol."},{"key":"1404_CR74","doi-asserted-by":"publisher","unstructured":"Tsimberidou, A. M. et al. Initiative for molecular profiling and advanced cancer therapy (IMPACT): an MD Anderson Precision Medicine Study. JCO Precis. Oncol. 2017 https:\/\/doi.org\/10.1200\/PO.17.00002 (2017).","DOI":"10.1200\/PO.17.00002"},{"key":"1404_CR75","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1182\/blood.V98.5.1392","volume":"98","author":"Q Pang","year":"2001","unstructured":"Pang, Q. et al. The Fanconi anemia complementation group C gene product: structural evidence of multifunctionality. Blood 98, 1392\u20131401 (2001).","journal-title":"Blood"},{"key":"1404_CR76","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-genet-102108-134222","volume":"43","author":"GL Moldovan","year":"2009","unstructured":"Moldovan, G. L. & D\u2019Andrea, A. D. How the Fanconi anemia pathway guards the genome. Annu. Rev. Genet. 43, 223\u2013249 (2009).","journal-title":"Annu. Rev. Genet."},{"key":"1404_CR77","first-page":"3","volume":"28","author":"M Levitus","year":"2006","unstructured":"Levitus, M., Joenje, H. & de Winter, J. P. The Fanconi anemia pathway of genomic maintenance. Cell Oncol. 28, 3\u201329 (2006).","journal-title":"Cell Oncol."},{"key":"1404_CR78","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1007\/s00018-016-2218-x","volume":"73","author":"D Lopez-Martinez","year":"2016","unstructured":"Lopez-Martinez, D., Liang, C. C. & Cohn, M. A. Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathway. Cell Mol. Life Sci. 73, 3097\u20133114 (2016).","journal-title":"Cell Mol. Life Sci."},{"key":"1404_CR79","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/mutage\/17.6.529","volume":"17","author":"M Bogliolo","year":"2002","unstructured":"Bogliolo, M. et al. The Fanconi anaemia genome stability and tumour suppressor network. Mutagenesis 17, 529\u2013538 (2002).","journal-title":"Mutagenesis"},{"key":"1404_CR80","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10577-008-9018-6","volume":"17","author":"E Kinoshita","year":"2009","unstructured":"Kinoshita, E., van der Linden, E., Sanchez, H. & Wyman, C. RAD50, an SMC family member with multiple roles in DNA break repair: how does ATP affect function? Chromosome Res. 17, 277\u2013288 (2009).","journal-title":"Chromosome Res."},{"key":"1404_CR81","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-genet-021920-092410","volume":"54","author":"B Bonilla","year":"2020","unstructured":"Bonilla, B., Hengel, S. R., Grundy, M. K. & Bernstein, K. A. RAD51 gene family structure and function. Annu. Rev. Genet. 54, 25\u201346 (2020).","journal-title":"Annu. Rev. Genet."},{"key":"1404_CR82","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1073\/pnas.0811965106","volume":"106","author":"J Hilario","year":"2009","unstructured":"Hilario, J., Amitani, I., Baskin, R. J. & Kowalczykowski, S. C. Direct imaging of human Rad51 nucleoprotein dynamics on individual DNA molecules. Proc. Natl. Acad. Sci. USA 106, 361\u2013368 (2009).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1404_CR83","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/467667a","volume":"467","author":"L Zou","year":"2010","unstructured":"Zou, L. DNA repair: a protein giant in its entirety. Nature 467, 667\u2013668 (2010).","journal-title":"Nature"},{"key":"1404_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms9829","volume":"6","author":"N Ameziane","year":"2015","unstructured":"Ameziane, N. et al. A novel Fanconi anaemia subtype associated with a dominant-negative mutation in RAD51. Nat. Commun. 6, 8829 (2015).","journal-title":"Nat. Commun."},{"key":"1404_CR85","first-page":"4225","volume":"127","author":"M Kleyman","year":"2014","unstructured":"Kleyman, M., Kabeche, L. & Compton, D. A. STAG2 promotes error correction in mitosis by regulating kinetochore-microtubule attachments. J. Cell Sci. 127, 4225\u20134233 (2014).","journal-title":"J. Cell Sci."},{"key":"1404_CR86","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09659-z","volume":"10","author":"G Mondal","year":"2019","unstructured":"Mondal, G., Stevers, M., Goode, B., Ashworth, A. & Solomon, D. A. A requirement for STAG2 in replication fork progression creates a targetable synthetic lethality in cohesin-mutant cancers. Nat. Commun. 10, 1686 (2019).","journal-title":"Nat. Commun."},{"key":"1404_CR87","unstructured":"Foundation Medicine, I. FoundationOne\u00aeCDx (F1CDx): Next generation sequencing oncology panel, somatic or germline variant detection system. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpma\/pma.cfm?id=P170019S052 (2023)."},{"key":"1404_CR88","unstructured":"Administration, U. S. F. a. D. LYNPARZA\u00ae (olaparib) tablets, for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/208558s028lbl.pdf (2014)."},{"key":"1404_CR89","unstructured":"Administration, U. S. F. a. D. TALZENNA\u00ae (talazoparib). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217439s000lbl.pdf (2018)."},{"key":"1404_CR90","unstructured":"Administration, U. S. F. a. D. TALZENNA\u00ae (talazoparib): Full prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/211651s012lbl.pdf (2018)."},{"key":"1404_CR91","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1074\/jbc.M608356200","volume":"282","author":"P Kowal","year":"2007","unstructured":"Kowal, P., Gurtan, A. M., Stuckert, P., D\u2019Andrea, A. D. & Ellenberger, T. Structural determinants of human FANCF protein that function in the assembly of a DNA damage signaling complex. J. Biol. Chem. 282, 2047\u20132055 (2007).","journal-title":"J. Biol. Chem."},{"key":"1404_CR92","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.trecan.2017.10.005","volume":"3","author":"M Nepal","year":"2017","unstructured":"Nepal, M., Che, R., Zhang, J., Ma, C. & Fei, P. Fanconi anemia signaling and cancer. Trends Cancer 3, 840\u2013856 (2017).","journal-title":"Trends Cancer"},{"key":"1404_CR93","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.molcel.2007.11.032","volume":"29","author":"K Gari","year":"2008","unstructured":"Gari, K., Decaillet, C., Stasiak, A. Z., Stasiak, A. & Constantinou, A. The Fanconi anemia protein FANCM can promote branch migration of Holliday junctions and replication forks. Mol. Cell 29, 141\u2013148 (2008).","journal-title":"Mol. Cell"},{"key":"1404_CR94","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01404-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01404-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01404-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T01:02:29Z","timestamp":1781485349000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01404-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1404"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01404-2","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.A.Y. reports research support from Artios, AstraZeneca, Bayer, Beigene, BioNTech, Blueprint, BMS, Boundless Bio, Clovis, Constellation, CPRIT, Cyteir, Department of De-fense, Eli Lilly, EMD Serono, Exelixis, Forbius, F-Star, GlaxoSmithKline, Genentech, Gil-ead, Golfers against Cancer, Haihe, Ideaya, ImmuneSensor, Insilico Medicine, Ionis, Ip-sen, Jounce, Karyopharm, KSQ, Kyowa, Merck, Mirati, Novartis, NIH\/NCI, Pfizer, Pliant, Prelude, Ribon Therapeutics, Regeneron, Repare, Roche, Rubius, Sanofi, Scholar Rock, Seattle Genetics, Synnovation, Tango, Tesaro, V Foundation, Vivace, Zenith, and Zental-is; consulting for AbbVie, Acrivon, Adagene, Almac, Aduro, Amgen, Amphista, Artios, Astex, AstraZeneca, Athena, Atrin, Avenzo, Avoro, Axiom, Baptist Health Systems, Bayer, Beigene, BioCity Pharma, Blueprint, Boxer, BridGene Biosciences, Bristol Myers Squibb, C4 Therapeutics, Calithera, Cancer Research UK, Carrick Therapeutics, Circle Pharma, Clovis, Cybrexa, Daiichi Sankyo, Dark Blue Therapeutics, Debiopharm, Diffu-sion, Duke Street Bio, 858 Therapeutics, EcoR1 Capital, Ellipses Pharma, EMD Serono, Entos, FoRx Therapeutics AG, F-Star, Genesis Therapeutics, Genmab, Glenmark, GLG, Globe Life Sciences, Grey Wolf Therapeutics, GSK, Guidepoint, Ideaya Biosciences, Idience, Ignyta, I-Mab, ImmuneSensor, Impact Therapeutics, Institut Gustave Roussy, Intellisphere, Jansen, Joint Scientific Committee for Phase I Trials in Hong Kong, Kyn, Kyowa Kirin, MEI pharma, Mereo, Merck, Merit, Monte Rosa Therapeutics, Natera, Nested Therapeutics, Nexys, Nimbus, Novocure, Odyssey Therapeutics, OHSU, On-coSec, Ono Pharma, Onxeo, PanAngium Therapeutics, Pegascy, PER, Pfizer, Piper-Sandler, Pliant Therapeutics, Prelude Therapeutics, Prolynx, Protai Bio, Radiopharma Theranostics, Repare, resTORbio, Roche, Ryvu Therapeutics, SAKK, Sanofi, Schrodinger, Servier, Synnovation, Synthis Therapeutics, Tango, TCG Crossover, TD2, Terremoto Biosciences, Tessellate Bio, Theragnostics, Terns Pharmaceuticals, Thryv Therapeutics, Tolremo, Tome, Trevarx Biomedical, Varian, Veeva, Versant, Vibliome, Vo-ronoi, Xinthera, Zai Labs, and ZielBio; and stock ownership in Seagen. S.F. reports research support from Abbisko, Antengene, BeiGene, BeyongSpring Phar-maceuticals, BioAtla, Boehringer Ingelheim, CUE Biopharma, DEKA Biosciences, Eli Lilly & Co., Exelixis, Greenfire Bio, Hookipa Biotech, IMV, Innovent Biologics, Jazz Pharma-ceuticlals, K-Group Beta, Lantern Pharma, Lyvgen Biopharm, MacroGenics, MediLink Therapeutics, Millennium Pharmaceuticals, Nerviano Medical Sciences, NeuPharma, NextCure, Ningbo NewBay Technology Development, Novartis, NovoCure, Nykode Therapeutics AS, Parexel International, PharmaMar USA, Pionyr Immunotherapeutics, PureTech Health, Qurgen, Shanghai Huaota Biopharmaceutical, Sellas Life Sciences Group, Soricimed Biopharma, SQZ Biotechnologies, Sumitomo Dainippon, Taiho Oncol-ogy, NCCN, Treadwell Therapeutics, Turnstone Biologics, Tyligand Bioscience, and Vi-rogin Biotech.D.S.H. reports research support from AbbVie, Adaptimmune, Adlai-Nortye, Amgen, As-telles, Astra-Zeneca, Bayer, Biomea, Bristol-Myers Squibb, Daiichi-Sankyo, Deciphera, Eisai, Eli Lilly, Endeavor, Erasca, F. Hoffmann-LaRoche, Fate Therapeutics, Genentech, Genmab, Immunogenesis, Infinity, Kyowa Kirin, Merck, Mirati, Navier, NCI-CTEP, Novar-tis, Numab, Pfizer, Pyramid Bio, Revolution Medicine, SeaGen, STCube, Takeda, TCR2, Turning Point Therapeutics, VM Oncology; consulting\/speaker\/advisory roles for 28Bio, Abbvie, Acuta, Adaptimmune, Alkermes, Alpha Insights, Amgen, Affini-T, Astellas, Aumbi-osciences, Axiom, Baxter, Bayer, Boxer Capital, BridgeBio, CARSgen, CLCC, COG, COR2ed, Cowen, Ecor1, EDDC, Erasca, Exelixis, Fate Therapeutics, F.Hoffmann-La Roche, Genentech, Gennao Bio, Gilead, GLG, Group H, Guidepoint, HCW Precision Oncology, Immunogenesis, Incyte, Inhibrix, InduPro, Janssen, Jounce Therapeutics Inc, Lan-Bio, Liberium, MedaCorp, Medscape, Novartis, Numab, Oncologia Brasil, ORI Capi-tal, Pfizer, Pharma Intelligence, POET Congress, Prime Oncology, Projects in Knowledge, Quanta, RAIN, Ridgeline, Revolution Medicine SeaGen, Stanford, STCube, Takeda, Tavistock, Trieza Therapeutics, T-Knife, Turning Point Therapeutics, WebMD, YingLing Pharma, and Ziopharm; travel support from AACR, ASCO, CLCC, Bayer, Genmab, SITC, and Telperian; and other ownership interests for Molecular Match (advi-sor), OncoResponse (founder, advisor), and Telperian (founder, advisor). S.A.P.P reports research funding (to institution) from AbbVie, ABM Therapeutics, Acepo-dia, Alkermes, Aminex Therapeutics, BioMarin Pharmaceutical, Boehringer Ingelheim, Bristol Myers Squib, Cerulean Pharma, Chugai Pharmaceutical Co., Curis, Cyclacel Pharmaceuticals, Daiichi Sankyo, Dohme, Eli Lilly, ENB Therapeutics, Epigenetix, Five Prime Therapeutics, F-Star Beta Limited, F-Star Therapeutics, Gene Quantum, Genmab A\/S, Gilead Sciences, GlaxoSmithKline, Helix BioPharma, Hengrui Pharmaceuticals, Hi-berCell, Immunomedics, Incyte, Jacobio Pharmaceuticals, Jazz Pharmaceuticals, Jiang-su Simcere Pharmaceutical Co., Loxo Oncology, Lytix Biopharma AS, Medimmune, Medivation, Merck Sharp, Nectin Therapeutics, Novartis Pharmaceuticals, Nurix, On-coNano Medicine, Pieris Pharmaceuticals, Pfizer, Phanes Therapeutics, Principia Bio-pharma, ProFoundBio US, Puma Biotechnology, Purinomia Biotech, Rapt Therapeutics, Replimune; Roche\/Blueprint, Seattle Genetics, Silverback Therapeutics, Shasqi, Synlogic Therapeutics, Taiho Oncology, Tallac Therapeutics, Tesaro, Theradex Oncology, Toragen Therapeutics, TransThera Bio, Xencor, ZielBio; and consulting for CRC Oncolo-gy and Lilly USA.A.N. reports research funding from NCI, EMD Serono, MedImmune, Healios Onc. Nutri-tion, Atterocor\/Millendo, Amplimmune, ARMO BioSciences, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol-Myers Squibb, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance Biosciences, Eli Lilly, Kymab, PsiOxus, Arcus Biosciences, NeoImmuneTech, Immune-Onc Therapeutics, Surface On-cology, Monopteros Therapeutics, BioNTech SE, Seven & Eight Biopharma, SOTIO Bio-tech AG, and GV20 Therapeutics. On advisory board\/Consulting fees from CTI, Deka Biosciences, Janssen Biotech, Mural Oncology, NGM Bio, PsiOxus Therapeutics, Im-mune-Onc Therapeutics, STCube Pharmaceuticals, OncoSec KEYNOTE-695, Genome & Company, CytomX Therapeutics, Nouscom, Merck Sharp & Dohme Corp, Servier, Lynx Health, AbbVie, Merck. Travel and accommodation expense from ARMO BioSci-ences, NeoImmuneTech, NGM Biopharmaceuticals. Honoraria for speaking engage-ments from AKH Inc, The Lynx Group, Society for Immunotherapy of Cancer (SITC), Ko-rean Society of Medical Oncology (KSMO), Scripps Cancer Care Symposium, ASCO Di-rect Oncology Highlights, European Society for Medical Oncology (ESMO), CME Outfit-ters. Research funding: The Texas Medical Center Digestive Diseases Center, Jeffery Modell Foundation, Immune Deficiency Foundation, Baxalta US Inc, Chao Physician-Scientist Foundation. Consultant\/Advisory board: Takeda, Pharming Healthcare Inc, and Horizon Therapeutics USA, Inc. Ad hoc consultancy speaker: Alfaisal University. J.R. reports research funding from 3H Pharmaceuticals; AADI Bioscience, Amgen, AstraZenneca, Beigene, Bicycle Therapeutics, BioAlta, Biotheryx, Blueprint Medicines, Bridgebio Pharma, C4 Therapeutics, Cancer Core Europe, Debio, Fog Pharmaceuticals, ForeBio, FusionPharma, GlaxoSmithKline, Hummingbird, Hutchinson MediPharma, Ideaya, Incyte, Kelun-Biotech, Kinnate, Linnaeus Therapeutics, Loxo Oncology, MapKu-re, Merck Sharp & Dohme, Merus, Mirati, MonteRosa, Novartis, Nuvectis Pharma, Pfiz-er, Relay, Roche Pharmaceuticals, Scorpion Therapeutics, Storm Therapeutics, Sym-phogen, Taiho, Tango Therapeutics, Tyra, Vall d\u2019Hebron Institute of and Oncology\/Cancer Core Europe, Yingli; consulting\/advisory board role for AADI Bioscience, Amgen, Boxer Capital, Bridgebio, Chinese University of Hong Kong, Cogent Biosciences, EcoR1 Capi-tal, Ellipses Pharma, Guidepoint; IONCTURA, Mekanistic, Merus, Molecular Partners, MonteRosa, Sardona, Tang Advisors, Vall d\u2019Hebron Institute of Oncology\/Ministero De Empleo Y Seguridad Social; travel support from European Society for Medical Oncology and Loxo Oncology; and other support from Boxer Capital, Chinese University of Hong Kong, Guidepoint; Tang Advisors, and Vall d\u2019Hebron Institute of Oncology\/Ministero De Empleo Y Seguridad Social. E.E.D. reports research or grant funding from Bayer Healthcare Pharmaceuticals, Im-munocore, Amgen, Aileron Therapeutics, Compugen, TRACON Pharmaceuticals, Un-umTherapeutics, Immunomedics, Bolt Therapeutics, Aprea Therapeutics, Bellicum Pharmaceuticals, PMV Pharma, Triumvira Immunologics, Seagen, Mereo BioPharma 5, Sanofi, Rain Oncology, Astex Pharmaceuticals, SOTIO, Poseida Therapeutics, Mersana Therapeutics, Genentech, Boehringer Ingelheim, Dragonfly Therapeutics, A2A Pharma-ceuticals, Volastra Therapeutics, and AstraZeneca. E.E.D. has consulted for or was on an advisory board of Bolt Therapeutics, Mersana Therapeutics, Orum Therapeutics, Summit Therapeutics, Fate Therapeutics, and PMV Pharma. E.E.D. has been a speaker for PMV Pharma and has received travel, accommodations, and\/or expenses from the American Society of Clinical Oncology (ASCO), the Li-Fraumeni Syndrome Association (LFSA), the Korean Society of Medical Oncology (KSMO), Rain Oncology, the Banner MD Anderson Cancer Center, and Triumvira Immunologics. D.J.V. reports other support from VisionSR and Bracco Diagnostics outside the submitted work. F.M.B. reports consulting for AbbVie, Aduro BioTech Inc., Alkermes, AstraZeneca, Daiichi Sankyo Co. Ltd., Calibr (a division of Scripps Research), DebioPharm, Ecor1 Capital, eFFECTOR Therapeutics, F. Hoffman-La Roche Ltd., GT Apeiron, Genentech Inc., Har-binger Health, IBM Watson, Incyte, Infinity Pharmaceuticals, Jackson Laboratory, Kolon Life Science, LegoChem Bio, Lengo Therapeutics, Menarini Group, OrigiMed, PACT Pharma, Parexel International, Pfizer Inc., Protai Bio Ltd., Samsung Bioepis, Seattle Genetics Inc., Tallac Therapeutics, Tyra Biosciences, Xencor, Zymeworks; advisory Committee membership for Black Diamond, Biovica, Eisai, FogPharma, Immunomedics, Inflection Biosciences, Karyopharm Therapeutics, Loxo Oncology, Mersana Therapeu-tics, OnCusp Therapeutics, Puma Biotechnology Inc., Seattle Genetics, Sanofi, Silver-back Therapeutics, Spectrum Pharmaceuticals, Theratechnologies, Zentalis; Sponsored Research (to the institution) from Aileron Therapeutics Inc. AstraZeneca, Bayer Healthcare Pharmaceutical, Calithera Biosciences Inc., Curis Inc., CytomX Therapeutics Inc., Daiichi Sankyo Co. Ltd., Debiopharm International, eFFECTOR Therapeutics, Genentech Inc., Guardant Health Inc., Klus Pharma, Takeda Pharmaceutical, Novartis, Puma Biotechnology Inc., Taiho Pharmaceutical Co.; Honoraria from Dava Oncology; and Other (Travel Related) from European Organization for Research and Treatment of Cancer (EORTC), European Society for Medical Oncology (ESMO), Cholangiocarcinoma Foundation, Dava Oncology.A.M.T reports grants Clinical Trial Research Support\/Grant Funding through the institution from 7 Hills Pharma, Immatics, OBI Pharma, Tempus, Parker Institute for Cancer Immunotherapy, Agenus, Novocure, Tvardi Therapeutics, Orionis, Tachyon, Vividion Therapeutics, AbbVie Macrogenics, Avaneon, Clinical and Translational Science Award Grant (CTSA) 1UM1TR0045906. CPRIT Grant: Cancer Prevention Research Institute of Texas (CPRIT) Precision Oncology Decision Support Core (RP150535). Consulting or Advisory Role: BrYet, NEX-I, OBI Pharma, Integra Connect. The remaining authors declare no competing financial or non-financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"220"}}